Tandem Diabetes Care (TNDM) has begun international shipments of its Tandem Mobi automated insulin pump to 12 countries across Europe and Israel, expanding access to its Control-IQ+ and Dexcom G7 powered system.
The international Tandem Mobi launch lands at a tricky moment for Tandem Diabetes Care investors. The share price is at US$15.72 after a 1-day share price return of 3.29%, but the 30-day share price return is down 26.64% and year-to-date share price performance is down 27.05%. The 1-year total shareholder return of 33.33% contrasts with a 5-year total shareholder return that is down 86.70%, suggesting short-term momentum has picked up from a low base even as the longer record still reflects significant past pain.
Capitalize on the renewed attention around Tandem Diabetes Care by scanning a handpicked 16 high quality undiscovered gems that could be setting up for their own product-driven rerating.Tandem Diabetes Care now has a fresh product story and a sharply mixed return profile. The business looks more established than the share price suggests, so does US$15.72 reflect fair value or lingering doubt?
Most Popular Narrative: 46% Undervalued
On the most followed narrative, Tandem Diabetes Care is assessed with a fair value of $29.20 against a last close of $15.72. This frames the current price as a wide gap to that scenario and places real emphasis on how its next phase of growth plays out.
Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels, supporting future revenue growth, margin expansion, and improved earnings.
See why 7 investors see Tandem Diabetes Care as 46% undervalued.
Result: Fair Value of $29.20 (UNDERVALUED)
Still, the Tandem Diabetes Care story can be knocked off course if new competitors slow pump adoption, or if the pharmacy rollout adds complexity and reimbursement risk.
Find out about the key risks to this Tandem Diabetes Care narrative.
Next Steps
Mixed messages around Tandem Diabetes Care can be confusing, so move quickly, review the full picture, and weigh the 3 key rewards.
Looking for more investment ideas beyond Tandem Diabetes Care?
You have seen how quickly sentiment around Tandem Diabetes Care can shift, so do not miss the chance to spot other potential outliers early.
- Target potential upside by scanning a curated pool of quality stocks trading below their estimated worth through the Simply Wall Street screener, starting with 32 high quality undervalued stocks.
- Prioritize resilience and sleep-at-night holdings by reviewing companies with stronger financial footing, filtered for you in the list of solid balance sheet and fundamentals (24 results).
- Hunt for compelling opportunities that many investors may be overlooking by running through a carefully constructed 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com